摘要
目的:监测地高辛血药浓度,为临床安全、有效、合理使用地高辛提供参考依据。方法:采用均相酶扩大免疫分析法,对2011-2012年我院164例次地高辛血药浓度进行监测。回顾性分析年龄、性别、病理状态、服药剂量、频次以及联合用药对地高辛血药浓度的影响。结果:监测数据在一般参考治疗浓度范围内占59.1%,平均血药浓度为(1.22±0.42)ng/ml,达到中毒浓度者占32.9%。年龄的增长、肾功能的减退、日剂量增加均可升高地高辛血药浓度,女性患者的血药浓度比男性患者略高,合并用药与地高辛血药浓度也有一定的相关性。结论:地高辛血药浓度的个体差异性较大,应结合患者生理病理、用药情况、血药浓度监测数据,综合评估地高辛药物浓度与其临床疗效的关系,制订个体化的给药方案,切实保证临床用药的合理性、安全性、有效性。
OBJECTIVE： To monitor blood concentration of digoxin, and to provide reference for safe, effective and rational use of digoxin in the clinic. METHODS： Homogeneous enzyme expand immunoassay was adopted to monitor 164 cases of blood concentration of digoxin in our hospital from 2011 to 2012. The effects of age, gender, pathological conditions, drug dose and frequency, drug combination on blood concentration of digoxin were analyzed. RESULTS： The results showed that 59.1% were within the normal referenced concentration range, with average concentration at （1.22 ± 0.42） ng/ml, and 32.9% reached toxic concentration. Age, decreasing of renal function, increasing daily dose could increase blood concentration of digoxin; the blood concentration of digoxin in female patients were slightly higher than in male; drug combination was also associated to blood concentration of digoxin. CONCLUSIONS： Due to individual difference of digoxin, we should consider about patients＇ physiology and pathology, drug use and blood concentration monitoring data, comprehensively evalute the relationship between digoxin concentration and its clinical efficacy, and finally develop individualized dosing regimen to ensure reasonable, safe and effective clinical drug use.
出处
《中国药房》
CAS
CSCD
2014年第2期136-139,共4页
China Pharmacy
关键词
地高辛
血药浓度监测
影响因素
个体化给药
Digoxin
Blood concentration monitoring
Influential factors
Individual administration
